Leveraging Butterfly Network's platform,
UltraSight seeks to enable patients to access cardiac imaging with
real-time AI guidance
TEL
AVIV, Israel, June 27,
2024 /PRNewswire/ -- Today, UltraSight, a digital
health pioneer transforming cardiac imaging through the power of
artificial intelligence, announced it has joined Butterfly Garden,
an artificial intelligence (AI) Marketplace launched by Butterfly
Network, Inc. ("Butterfly") (NYSE: BFLY), a digital health company
transforming care through the power of portable,
semiconductor-based ultrasound technology and intuitive
software.
UltraSight and Butterfly have partnered to increase patient
access to cardiac care by enabling more healthcare professionals to
perform cardiac ultrasound. Subject to regulatory approvals and
authorizations, UltraSight aims to integrate and deploy its
real-time AI guidance software on Butterfly's imaging platform and
build the software for use with Butterfly's single-probe,
whole-body handheld ultrasound system.
Cardiovascular disease (CVD) is the leading global cause of
death, accounting for an estimated 18 million deaths yearly. Today
patients face significant delays in receiving crucial cardiac
testing due to a fragmented market full of system bottlenecks, in
addition to a national shortage of expert sonographers.
UltraSight's mission is to empower any medical professional,
including novice users with no prior sonography experience, to
confidently conduct echocardiographic examinations and capture
diagnostic quality cardiac ultrasound images at the point of care.
Achieving compatibility with the most prominent handheld ultrasound
device companies in the market, such as Butterfly, facilitates the
company's goal of increasing access to cardiac care and reducing
system bottlenecks for patients.
"Joining the Butterfly Garden marks an important moment in our
mission to revolutionize cardiac care," said Davidi Vortman, CEO of UltraSight. "By
integrating our real-time AI guidance software with Butterfly's
cutting-edge ultrasound technology, we are poised to transform the
landscape of cardiac imaging. This collaboration will empower
healthcare professionals, regardless of their experience level, to
perform accurate and timely cardiac ultrasound exams at the point
of care. Together, we will break down existing barriers in cardiac
care, ensuring that more patients receive the critical diagnostics
they need, when and where they need it most."
"We are thrilled to partner with UltraSight to bring their AI
guidance software to Butterfly devices in an effort to mitigate the
pressing issue of sonographer shortages, among other workforce
challenges, impacting medical communities around the world," said
Darius Shahida, chief strategy
officer of Butterfly Network. "UltraSight and Butterfly are jointly
dedicated to making healthcare more efficient, effective and
accessible through high-quality ultrasound that's easy-to-use and
globally available."
In August 2023, Butterfly Network
launched Butterfly Garden, allowing third-party developers access
to its proprietary SDK and APIs to build new AI applications that
work in conjunction with Butterfly's imaging platform, bringing
with it access to the largest point-of-care ultrasound customer
base. UltraSight, with capabilities to provide more medical
professionals with the ability to take high-quality diagnostic
images of the heart, has the potential to close the gap between
novice and skilled Butterfly ultrasound users, and is an ideal
match for the program.
When paired with ultrasound devices, and following the
appropriate regulatory clearance for each device, UltraSight's
underlying AI neural network can predict the position of the
ultrasound probe relative to the heart based on the ultrasound
video stream and guide the user on maneuvering the probe to capture
diagnostic quality cardiac images.
UltraSight's partnership with Butterfly follows a series of
recent collaborations with other industry leaders such as Mayo
Clinic and EchoNous. For more information about UltraSight, visit
www.ultrasight.com. For more information about Butterfly, visit
www.butterflynetwork.com.
About UltraSight
UltraSight's mission is to make diagnostic imaging more
accessible by empowering medical professionals to successfully
acquire timely and accurate cardiac ultrasound images anywhere.
UltraSight's AI-driven software offers real-time guidance, making
cardiac ultrasound accessible and efficient, which may lead to
quicker diagnoses and improved patient care. In 2022, UltraSight
won the Bristol Myers Squibb Improving Cardiovascular Disease
Outcomes Challenge as the most "innovative cardiac technology."
Additionally, the company was awarded a patent for its real-time
guidance solution for ultrasound devices. UltraSight's software has
FDA 510(k) Clearance, is UKCA and CE Marked, and has Israeli AMAR
Clearance to assist medical professionals in performing cardiac
ultrasound scans. For more news and information, visit
our website or follow UltraSight on LinkedIn and
Twitter
About Butterfly Network
Founded by Dr. Jonathan Rothberg
in 2011, Butterfly Network is a digital health company with a
mission to democratize medical imaging by making high-quality
ultrasound affordable, easy-to-use, globally accessible, and
intelligently connected, including for the 4.7 billion people
around the world lacking access to ultrasound. Butterfly created
the world's first handheld single-probe, whole-body ultrasound
system using semiconductor technology, Butterfly iQ. The company
has continued to innovate, leveraging the benefits of Moore's Law,
to launch its second-generation Butterfly iQ+ in 2020, and
third-generation iQ3 in 2024 – each with increased processing power
and performance enhancements. The disruptive technology has been
recognized by TIME's Best Inventions, Fast Company's World Changing
Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among
other accolades. With its proprietary Ultrasound-on-Chip™
technology, intelligent software, and educational offerings,
Butterfly is paving the way to mass adoption of ultrasound for
earlier detection and remote management of health conditions around
the world. Butterfly devices are commercially available to trained
healthcare practitioners in areas including, but not limited to,
parts of Africa, Asia, Australia, Europe, the Middle
East, North America and
South America; to learn more about
available countries, visit:
www.butterflynetwork.com/choose-your-country.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ultrasight-joins-butterfly-garden-to-expand-ai-real-time-guidance-across-point-of-care-ultrasound-devices-302184449.html
SOURCE UltraSight